Biosimilar and Follow-on Biologics Market Report by IMARC Group Recently Published by MarketPublishers.com

20 Oct 2011 • by Natalie Aster
Biosimilar and Follow-on Biologics Market Report by IMARC Group Recently Published by MarketPublishers.com

LONDON – Biosimilars in the US are believed to soon represent a multi-billion dollar market as they would be posing stiff competition to as many as twenty biological molecules during 2011-2020. This market, unlike small molecule generics, is expected to be more akin to a marathon than a sprint. Moreover the competition between branded biological drugs and their biosimilar counterparts is reported to be more of a brand-brand competition than a brand-generic competition.

New market research studyBiosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)prepared by IMARC Group provides an analytical and statistical insight into the US biosimilar market. The study looks deep and draws upon analysis of six aspects of the US biosimilar market. It covers an in-depth discussion of the past landscape of the market and provides detailed forecasts regarding its development and future trends.

Report Details:

Title: Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)
Published: October, 2011
Pages: 152
Price: US$ 1,200

Reports Contents:

1 MARKET DEFINITIONS & RESEARCH METHODOLOGY

2 EXECUTIVE SUMMARY

3 THE US BIOSIMILAR MARKET LANDSCAPE

4 US BIOSIMILAR MARKET: CURRENT EXPERIENCE
4.1 The Performance of Growth Hormone Biosimilars Has Been Dismal So Far
4.2 Pediatrics Represent the Prime Customer Base for Growth Hormones
4.3 Omnitrope Was Launched with an Inconvenient Delivery Device
4.4 Prescribing Patterns for Omnitrope
4.5 Uptake is Likely to Increase with the Accumulation of Post-Market Safety Data


5 US BIOSIMLAR MARKET: HOW MUCH PRICE, VOLUME & SALES EROSION WILL RESULT
5.1 Omnitrope Cannot be Taken as a Benchmark to Gauge the Performance of Other Biosimilars
5.2 The European Uptake of ESA & GCSF Biosimilars Give Us a Very Positive Outlook for the US
5.3 Models for Biosimilar Volume Erosion Across Various Biological Classes
5.4 Models for Biosimilar Price Erosion Across Various Biological Classes
5.5 Models for Biosimilar Sales Erosion Across Various Biological Classes


6 US BIOSIMILAR MARKET: CURRENT TRENDS & FORECAST BY DRUG
6.1 Growth Hormones
  6.1.1 Somatropin (Genotropin/Humatrope/Other HGH)
    6.1.1.1 Drug Overview
    6.1.1.2 Current Brand & Biosimilar Sales

    6.1.1.3 Brand & Biosimilar Forecast (2011-2020)
6.2 Erythropoiesis Stimulating Agents
  6.2.1 Epoetin Alfa (Epogen/Eprex)
    6.2.1.1 Drug Overview
    6.2.1.2 Historical Brand Sales
    6.2.1.3 Brand & Biosimilar Forecast (2011-2020)
6.3 Granulocyte Colony Stimulating Factor
  6.3.1 Filgrastim (Neupogen)
    6.3.1.1 Drug Overview
    6.3.1.2 Historical Brand Sales
    6.3.1.3 Brand & Biosimilar Forecast (2011-2020)
  6.3.2 Pegfilgrastim (Neulasta)
    6.3.2.1 Drug Overview
    6.3.2.2 Historical Brand Sales
    6.3.2.3 Brand & Biosimilar Forecast (2011-2020)
6.4 Insulin
  6.4.1 Insulin Lispro (Humalog)
    6.4.1.1 Drug Overview

More new market research reports by the publisher can be found at IMARC Group page.

 

CONTACTS

The Market Publishers, Ltd.

Mrs. Tanya Rezler

Tel: +44 208 123 2220

Fax: +44 207 900 3970

ps@marketpublishers.com

www.MarketPublishers.com